Quantcast

Latest Sunitinib Stories

2011-06-15 02:00:00

TUEBINGEN, Germany, June 15, 2011 /PRNewswire/ -- igoommatics biotechnologies GmbH, a biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, announced today that the first patients have been vaccinated in the IMPRINT study, a pivotal Phase III trial with IMA901, the company's lead cancer vaccine for the treatment of renal cell carcinoma (RCC). The trial is designed to demonstrate the overall survival benefit of IMA901 in...

2011-06-05 10:00:00

DURHAM, N.C., June 5, 2011 /PRNewswire/ -- Argos Therapeutics today announced that new data from its Phase 2 combination study of its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib showed improvement over expectations for sunitinib alone in progression-free survival (PFS) in newly diagnosed metastatic RCC patients with unfavorable prognosis.

2011-06-03 13:30:48

In data presented at The American Society of Clinical Oncology (ASCO) Annual Meeting, cancer researchers found that the brain tumor vaccine HSPPC-96 for treating recurrent gliobastoma (GBM) has a favorable safety profile and extends survival by two to three times more than the current median survival rate.

2011-06-01 07:00:00

DURHAM, N.C., June 1, 2011 /PRNewswire/ -- Argos Therapeutics announced today that its Arcelis(TM) immunotherapy for the treatment of renal cell carcinoma (RCC), AGS-003, in combination with sunitinib demonstrated a strong immunologic response that correlated to improved clinical outcomes.

2011-06-01 00:24:00

EAST HANOVER, N.J., June 1, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).

2011-05-20 17:14:00

MANHATTAN BEACH, Calif., May 20, 2011 /PRNewswire/ -- The Pfizer drug Sutent® (sunitinib) has been approved for the treatment of advanced pancreatic neuroendocrine tumors by the U.S. Food and Drug Administration (FDA).

2011-05-20 15:34:00

SILVER SPRING, Md., May 20, 2011 /PRNewswire-USNewswire/ -- The U.S.

2011-05-10 01:30:00

WAYNE, N.J., May 10, 2011 /PRNewswire/ -- Bayer HealthCare Pharmaceuticals Inc. announced today that its investigational compound regorafenib (BAY 73-4506) has been granted Fast Track designation by the U.S.

2011-05-06 08:54:00

SILVER SPRING, Md., May 6, 2011 /PRNewswire-USNewswire/ -- On Thursday, the U.S.

2011-05-05 17:50:00

EAST HANOVER, N.J., May 5, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today that the US Food and Drug Administration (FDA) approved Afinitor® (everolimus) tablets for the treatment of progressive neuroendocrine tumors of pancreatic origin (PNET) in patients with unresectable, locally advanced or metastatic disease(4).


Word of the Day
shavie
  • A trick or prank.
The word 'shavie' is related to 'shave'.